Kenvue Inc. (NYSE:KVUE) Shares Purchased by Van Lanschot Kempen Investment Management N.V.

Van Lanschot Kempen Investment Management N.V. lifted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 1.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,353,596 shares of the company's stock after purchasing an additional 20,614 shares during the quarter. Van Lanschot Kempen Investment Management N.V. owned about 0.07% of Kenvue worth $28,899,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after acquiring an additional 1,636,741 shares during the period. Massachusetts Financial Services Co. MA grew its position in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Geode Capital Management LLC grew its position in Kenvue by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after purchasing an additional 1,391,854 shares during the period. Franklin Resources Inc. raised its stake in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Kenvue by 2.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,972,777 shares of the company's stock valued at $533,169,000 after buying an additional 561,570 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of Kenvue stock traded up $0.28 on Friday, reaching $23.03. 22,249,585 shares of the stock were exchanged, compared to its average volume of 17,113,054. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.19 billion, a PE ratio of 43.45, a PEG ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The business has a fifty day moving average price of $23.03 and a two-hundred day moving average price of $22.43.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.56%. Kenvue's dividend payout ratio (DPR) is 154.72%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price on the stock. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Finally, Citigroup raised their price objective on Kenvue from $21.00 to $22.00 and gave the company a "neutral" rating in a report on Monday, April 14th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.